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ABSTRACT
Background. The paper describes a randomized controlled trial of targeting cognitive behavioural
therapy (CBT) during prodromal or early signs of relapse in schizophrenia. We hypothesized that
CBT would result in reduced admission and relapse, reduced positive and negative symptoms, and
improved social functioning.
Method. A total of 144 participants with schizophrenia or a related disorder were randomized to
receive either treatment as usual (TAU) (N=72) or CBT+TAU (N=72). Participants were pro-
spectively followed up between entry and 12 months.
Results. At 12 months, 11 (15.3%) participants in the CBT group were admitted to hospital com-
pared to 19 (26.4%) of the TAU group (hazard ratio=0.53, P=0.10, 95% CI 0.25, 1.10). A total of
13 (18.1%) participants in CBT relapsed compared to 25 (34.7%) in TAU (hazard ratio=0.47,
P<0.05, 95% CI 0.24, 0.92). In addition, the CBT group showed signiﬁcantly greater improvement
in positive symptoms, negative symptoms, global psychopathology, performance of independent
functions and prosocial activities.
Conclusions. The study provides evidence for the feasibility and eﬀectiveness for targeting CBT on
the appearance of early signs of relapse in schizophrenia. The results are discussed in context of the
study’s methodological limitations.
INTRODUCTION
There is growing evidence that CBT is eﬀective
in reducing the severity of positive and negative
symptoms associated with schizophrenia (Tar-
rier et al. 1993, 1998; Drury et al. 1996a, b ;
Kuipers et al. 1997; Pinto et al. 1999; Sensky
et al. 2000; Turkington et al. 2002). Four trials
provide post-treatment follow-up (Kuipers et al.
1998; Drury et al. 2000; Sensky et al. 2000;
Tarrier et al. 1999, 2000). Kuipers et al. (1998)
and Sensky et al. (2000) do not report relapse
rates for their participants. Kuipers et al. (1998)
found that at 9 months those who had received
CBT continued to show improvements in de-
lusional distress and frequency of halluci-
nations. Sensky et al. (2000) found that the CBT
group continued to improve on measures of
positive symptoms, depression and negative
symptoms. Tarrier et al. (1999) reported 12-
month follow-up results for CBT compared to
supportive counselling (SC) or routine care
(RC). Participants in CBT continued to show
signiﬁcant treatment eﬀects for both positive and
negative symptoms. There were no signiﬁcant
diﬀerences between the three groups for relapse
at this follow-up. At 2 years, Tarrier et al. (2000)
found that there were signiﬁcant diﬀerences for
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both CBT and SC over RC for positive and
negative symptoms. There was no signiﬁcant
diﬀerence between CBT and SC groups. In terms
of relapse, there were no signiﬁcant diﬀerences
between CBT and SC. These groups were com-
bined for comparison with RC. The number of
relapses was greater in the RC group (11/28,
39%) compared to the combined group (13/59,
27%). In a 5-year follow-up of 40 participants
randomized to either CBT or ATY (recreational
activities with informal support), Drury et al.
(2000) found no diﬀerences between the two
groups with regards to number of relapses or
admissions, or time spent in acute in-patient
facilities. However for those individuals who
received CBT and did not have more than one
relapse, the eﬀects of CBT endured. These par-
ticipants continued to show reduced self-rated
delusional conviction, observer rated delusional
ideation, thought disorder, hallucinations, and
increased perception of control over psychosis.
Therefore, it appears that the eﬀects of CBT
on positive and negative symptoms endure over
time and that strategies aimed at preventing or
minimising relapse should enhance the dura-
bility of CBT, or indeed other interventions for
schizophrenia. This is especially important given
that two prospective studies of ﬁrst episode
schizophrenia (Shepherd et al. 1989; Wiersma
et al. 1998) show an increased incidence of drug-
resistant symptoms following relapse. One well-
developed strategy for the prevention of relapse
in schizophrenia is the monitoring of prodromes
or ‘early signs’ of relapse (Birchwood & Spen-
cer, 2001). Eight prospective studies of early
signs (Subotnik & Neuchterlein, 1988; Birch-
wood et al. 1989; Jolley et al. 1990; Marder et al.
1991, 1994; Tarrier et al. 1991; Gaebel et al.
1993; Jorgensen, 1998) conﬁrm that relapse
is almost always preceded by non-psychotic
symptoms such as anxiety and depression, and
low-level psychotic symptoms such as ideas of
reference. However, the occurrence of early
signs does not necessarily mean that relapse is in-
evitable. Three studies (Breier & Strauss, 1983;
McCandless-Glimcher et al. 1986; Hultman
et al. 1997) show that patients monitor and
regulate their symptoms in order to prevent re-
lapse. For example, Hultman et al. (1997) found
that patients with a withdrawal-orientated
coping style were more likely to relapse than
patients who had a socially-orientated coping
style.Amongpatientswithbipolar disorder,Lam
& Wong (1997) found that participants spon-
taneously described using cognitive behavioural
strategies to prevent depressive relapse and
behavioural strategies to prevent manic relapse.
Lam et al. (2001) found that participants who
used coping strategies to prevent relapse were
less likely to experience either a depressive or a
manic relapse during an 18-month naturalistic
study. In a 12 month pilot study of CBT for the
prevention of relapse in bipolar disorder, Lam
et al. (2000) found that participants who received
CBT had fewer bipolar episodes, higher social
functioning, less ﬂuctuation in symptoms of
mania and depression and improved medication
compliance. Perry et al. (1999) evaluated the
eﬃcacy of teaching patients with bipolar dis-
order to identify early signs of relapse and ob-
tain conventional psychiatric treatment. Over
18 months, there was a signiﬁcant reduction in
manic relapses and improvements in overall
social functioning and employment for the
experimental group.
To date, there have been no controlled trials
of CBT for patients with schizophrenia to pre-
vent potential relapses once early signs have
been identiﬁed, although this idea has been fre-
quently written about (e.g. Birchwood, 1995;
Gumley et al. 1999). Based on the preceding
literature this is an approach that holds prom-
ise, not only for the prevention of psychotic
relapse, but also as a method for enhancing
symptomatic recovery and improved social
functioning. Therefore, a pragmatic clinical trial
with random allocation and prospective follow-
up, was designed to evaluate whether CBT de-
livered on the appearance of prodromal early
signs of psychotic relapse resulted in reduced
admission and relapse, and as a secondary out-
come, reduced positive and negative symptoms,
and improved social functioning among in-
dividuals with schizophrenia.
METHOD
Procedure
The study was conducted between June 1997
and December 2000. After obtaining ethical
approval from Local Research Ethics Com-
mittees in each NHS Trust potentially eligible
patients who were receiving treatment from
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local community mental health teams (CMHTs)
were identiﬁed though hospital and clinic data-
bases in two NHS Trusts in the West of Scot-
land (six CMHTs in Ayrshire and two CMHTs
in Glasgow). The locality area for these teams
included a population of approximately 460 000
encompassing rural, suburban, and metropoli-
tan areas. The case notes of these patients were
then screened, and the consultant psychiatrist
was approached to give permission for the as-
sessment of those meeting inclusion criteria at
that stage. Patients were then approached to
give informed written consent and, if consent
was granted, were interviewed to conﬁrm entry
criteria and provide baseline assessments. Entry
required that patients fulﬁlled DSM-IV (Amer-
ican Psychiatric Association, 1994) criteria for
schizophrenia or a related disorder conﬁrmed
by the Structured Clinical Interview for DSM-
IV (First et al. 1994), were aged between 18 and
65, were receiving antipsychotic medication,
and were considered relapse prone. Patients
were considered relapse prone if they had one
or more of the following characteristics : (1) a
history of relapse in the last 2 years; (2) their
keyworker viewed them as living in a stressful
environment (e.g. a home environment charac-
terized by high levels of expressed emotion); (3)
living alone or socially isolated; (4) non-
adherence with antipsychotic medication (where
this was viewed as problematic by the partici-
pant’s keyworker and/or prescribing psy-
chiatrist) ; and (5) being on a neuroleptic dosage
reduction programme. Patients were excluded
if they were a non-English speaker, had organic
brain disorder, presence of signiﬁcant learning
disability, severe positive psychotic symptoms
(rating of o5 on the positive scale of the Posi-
tive and Negative Syndrome Scale (PANSS)
(Kay et al. 1987), a primary drug or alcohol
dependence disorder (based on the opinion of
the key worker), or being in receipt of a con-
current psychotherapy outside the study. The
sample size was calculated on the basis that a
sample of 150 participants (75 per group),
would have 89% power to detect at P<0.05
an estimated reduction in relapse/exacerbation
rates from 50% (e.g. Gaebel & Pietzcker, 1985)
in the TAU alone group to 25% in the CBT
group (Pocock, 1996).
Participants were consecutively assessed by a
research psychiatrist (M.O’G, R.S.) or a clinical
psychologist (C.W.) and recruited into the study
prior to randomization. After the interview
the patient was randomized according to pre-
determined envelopes containing the treatment
group to which participants would be allocated
(TAU or CBT) devised by one of the authors
(K.P.), which was unbeknown to the assessors,
therapist or participants. No restrictions were
placed on the randomization procedure with
regards to any particular demographic or clini-
cal variables. A member of the research team
(L.M., J.R. or A.G.) opened an envelope that
informed as to which group individual partici-
pants were to be allocated. Another member of
the team witnessed this procedure, and the en-
velope was placed in the participant’s caseﬁle.
Two research nurses (L.M. and J.R.), who were
not blind to the treatment allocation of partici-
pants, conducted follow-up assessments. In ad-
dition, the research nurses undertook regular
monthly liaison with the participants’ treatment
teams to determine if there was evidence of a
relapse. If there was evidence of a relapse, the
participant was seen by the research nurse using
the standardized psychiatric interview (Kay
et al. 1987) prior to the next planned assessment
date (12, 26, or 52 weeks) to date the relapse
accurately. For participants who dropped out of
the study, data on admission were taken from
the case notes. The research nurse also fed back
on progress of participants receiving CBT and
their early signs monitoring. If a participant did
not return early signs, the research nurse would
check with the participant’s keyworker regard-
ing any symptom changes or circumstances/
stressors, which were suggestive of an increase in
relapse risk. If there was an increase in relapse
risk, the research nurse informed the therapist
who then contacted the patient to conduct an
assessment for targeted CBT.
Assessments
Assessments were carried out at entry, 12, 26
and 52 weeks using a battery of measures.
Positive and negative symptoms were measured
using the PANSS (Kay et al. 1987). The PANSS
is a 30-item observer rated scale. Each item is
rated on a severity scale ranging from 1 (absence
of psychopathology) to 7 (extremely severe).
The sum of the ﬁrst seven items constitutes the
positive scale score (range 7 to 49): delusions,
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conceptual disorganisation, hallucinatory be-
haviour, excitement, grandiosity, suspiciousness/
persecution and hostility. The sum of items
8 to 14 constitutes the negative scale score (e.g.
blunted aﬀect, emotional withdrawal). The
sum of items 15 to 30 constitutes the global
psychopathology scale score (e.g. somatic con-
cern, anxiety). The raters were trained using
interviews with patients, either face to face or
on video. Interclass correlations for the posi-
tive, negative and global subscales were 0.91,
0.87, 0.72 respectively and for the total score
0.80. Relapse was deﬁned as an admission to
hospital or an increase in psychotic symptoms
for minimum of 7 days. An increase in positive
symptoms was based on participants’ positive
symptoms rated at entry on the positive scale of
PANSS. Those who scored o3 (mild to mod-
erate) on any one item of the positive scale of the
PANSS classiﬁed as having residual symptoms;
all other participants were classiﬁed as having
minimal or no residual positive symptoms. For
those with residual symptoms, a 50% increase
in the positive scale score, sustained for at least
1 week, was deﬁned as meeting criteria for
relapse. For those without residual symptoms,
an increase in positive symptoms (rated o3),
sustained for at least 1 week, was deﬁned as
meeting criteria for a relapse. Psychological dis-
tress was measured using the Brief Symptom
Inventory (BSI) (Derogatis & Melisaratos,
1983). Negative appraisals of psychosis were
assessed using the Personal Beliefs about Illness
Questionnaire (PBIQ) (Birchwood et al. 1993).
The Rosenberg Self-Esteem Scale (RSES)
(Rosenberg, 1965) was selected as a measure of
negative appraisals of self. The Social Func-
tioning Scale (SFS) (Birchwood et al. 1990) was
used to assess social role and behavioural func-
tioning across seven basic areas of community
functioning: social engagement, interpersonal
behaviour, prosocial activities, recreation, inde-
pendence (performance and competence) and
employment. A criterion of clinical signiﬁcance
was used to deﬁne whether or not a participant
achieved clinically signiﬁcant improvement or
deterioration in their social functioning deﬁned
as whether an individual’s outcome response
fell outside the range of the population by two
standard deviations (higher or lower) from the
pre-treatment baseline score (Jacobson& Truax,
1991). In addition, medication and psychiatric
care usage was monitored during the 12-month
follow-up period. Total dose of antipsychotic
medication at each assessment was calculated as
chlorpromazine equivalents in milligrams per
day (Atkins et al. 1997). Type of antipsychotic
medication was also noted.
Treatment groups
Treatment as usual (TAU)
All participants continued to receive their on-
going usual treatment, which was overseen by
the participants’ consultant psychiatrist. The
core components of TAU entailed ongoing
medication, regular psychiatric review, and reg-
ular follow-up from a keyworker, usually a
community mental health nurse. All partici-
pants had access to a wider multidisciplinary
community mental health team.
Cognitive behavioural therapy
A description of the treatment protocol has been
detailed in Gumley & Power (2000). A clinical
psychologist (A.G.) provided all CBT sessions.
CBT was divided into two phases. A ﬁve-session
engagement phase was delivered between entry
and 12 weeks. An intensive targeted phase (2 to 3
sessions per week) was delivered at the appear-
ance of early signs of relapse.
Engagement began with a description of the
cognitive model of relapse (Birchwood, 1995;
Gumley et al. 1999), which emphasized how the
early signs of relapse (e.g. racing thoughts, un-
usual experiences, suspiciousness) can trigger
negative beliefs concerning relapse (e.g. ‘ I’m
going to be relapse and end up in hospital ’).
An explanation of how these beliefs lead to
increased fear, depression or helplessness and
potentially unhelpful coping behaviours (e.g.
withdrawal, avoidance of services, substance
use) was given. Participants were encouraged to
test this model of relapse through discussion of
their own prior experiences. Participants who
were reluctant to accept that they had an illness
were still encouraged to consider their experi-
ence of relapse, particularly in terms of prior
hospital admissions. An individualized case
formulation of the cognitive behavioural factors
associated with relapse, and an idiosyncratic
early signs monitoring questionnaire incor-
porating these factors was developed (Tait
et al. 2002). An assistant psychologist or trial
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secretary, who were not involved in the assess-
ment of outcome, dispatched the questionnaires
toparticipantsonafortnightlybasis.Participants
were instructed to complete and return their
questionnaires using a stamped addressed en-
velope enclosed for their use. Early signs moni-
toring continued for the duration of the trial.
This early signs monitoring procedure was as-
sociated with an adherence rate of 83%.
Targeted CBT was initiated when there was
an increase in a participant’s self-reported early
signs. Assessment for targeting was initiated if
there was a failure to return early signs ques-
tionnaires on more than one consecutive oc-
casion and if treatment teams reported symp-
tom changes or circumstances/stressors, which
were suggestive of an increase in relapse risk.
Targeted CBT began with a detailed assessment
of the evidence for and against emerging re-
lapse, in order to identify potential false alarms
and to provide a test of the case formulation.
Thereafter, the order of treatment tasks was as
follows: identify and target beliefs and beha-
viours that increased risk to self or others ;
identify and target beliefs and behaviours ac-
celerating relapse; and develop alternative be-
liefs and reinforce through behaviour change
(Davidson, 2000). The therapist elicited any
further negative beliefs concerning relapse. In
order to reduce participants’ fear or helplessness
about relapse, early intervention was framed as
an opportunity to develop mastery over an ap-
parently uncontrollable and inevitable process.
Alternative beliefs of relapse as a controllable
process were developed (e.g. ‘ If I can learn to
ignore unwanted thoughts, then I’ll be less
scared’) and were tested using within and be-
tween session behavioural experiments. Beha-
vioural experiments involved strengthening
existing coping skills or developing novel cop-
ing strategies. Emphasis was given to developing
strategies to counteract ruminative withdrawal
and avoidance, to enhance coping with criticism
from others, and to avoid the use of alcohol and
illicit drugs. In addition cognitive and beha-
vioural strategies were employed to reduce in-
trusive cognitive phenomena such as ﬂashbacks
to previous episodes through guided discovery
and cognitive restructuring of problematic ap-
praisals concerning anger, trust, helplessness,
and self-blame (Resick & Schnicke, 1993). All
participants were encouraged to adhere with
their antipsychotic medication. Where partici-
pants expressed concern regarding the toler-
ability of their medication they were encouraged
to discuss this with their keyworker and con-
sultant psychiatrist. In cases where participants
did not adhere to medication, positive and
negative beliefs about adherence and non-
adherence were elicited and summarized. Where
participants wished to continue to avoid medi-
cation this was also discussed with their con-
sultant psychiatrist. Where possible, and in
order to preserve collaboration, participants
were encouraged to treat their non-adherence as
a behavioural experiment. Anticipated beneﬁts
and problems were considered. Where problems
were anticipated, the implementation of existing
or potential coping skills was discussed, and as-
sistance was given to participants in rehearsing
and implementing these. In addition, as part of
this experimental approach to treatment thresh-
olds for reinitiating medication were agreed.
Based on participants’ ratings of their early
signs questionnaire targetedCBTwas terminated
when these ratings of early signs had reduced
to baseline levels. Targeted CBT was concluded
by a review of strategies employed during treat-
ment, and an examination of the evidence for
and against participants’ negative beliefs and
their alternative beliefs concerning relapse.
Statistical analysis
All analyses were according to the intention-
to-treat principle. Baseline characteristics were
summarized as number of subjects (%) for
categorical covariates and mean (standard de-
viation) for continuous covariates. For the
statistical models that used baseline covariates
as adjusting factors, missing data on these
covariates were imputed using the conditional
mean based on centre, sex and age. The primary
outcomes of time to ﬁrst hospital admission
and time to ﬁrst relapse were displayed using
Kaplan–Meier survival plots, and the diﬀerence
between the two treatment groups estimated
using Cox proportional hazards models. This
treatment eﬀect was adjusted for baseline
covariates listed in Table 1. The secondary
outcomes of change over baseline at 12 months
in PANSS components (positive, negative, glo-
bal), and the components of Social Functioning
Scores (withdrawal, interpersonal, indepen-
dence performance, independence competence,
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recreation, employment), and the equivalent
chlorpromazine dose, were compared between
the two treatments using normal linear models,
with and without adjustment for baseline
covariates as above. In addition, amount of
treatment received and number of days in hos-
pital were summarized for each treatment
group. Clinically signiﬁcant changes in the
Social Functioning Scores were deﬁned as any
movement of at least plus (higher) or minus
(lower) 2 sample standard deviations (calculated
without imputation of missing data) from 12
months over baseline. The number of subjects
with a lower change, and then an upper change,
was then compared between the two groups
using Fisher Exact tests. The number of partici-
pants needed to be treated for 1 year to avert
1 event was deﬁned as the reciprocal of the dif-
ference in the raw event rates between the TAU
and CBT groups. No adjustment has been made
for multiple testing. All analyses performed
using SAS 8.2 for Windows NT.
RESULTS
Patient characteristics
The ﬂow of participants into the study is illu-
strated in Fig. 1. A total of 144 participants were
Table 1. Baseline characteristics by randomized treatment group. Data shown are number of subjects
(%) for categorical data, mean (standard deviation) for continuous data
Factor Level/units CBT TAU
Age years 35.8 (9.6) 36.7 (10.1)
Sex Male 54 (75.0%) 51 (70.8%)
Female 18 (25.0%) 21 (29.2%)
Primary diagnosis Schizophrenia 59 (81.9%) 59 (81.9%)
Schizoaﬀective 12 (16.7%) 10 (13.9%)
Schizophreniform 1 (1.4%) 1 (1.4%)
Delusional disorder 0 (0%) 1 (1.4%)
Psychotic disorder NOS 0 (0%) 1 (1.4%)
Medication Atypical 41 (56.9%) 41 (56.9%)
Typical 31 (43.1%) 31 (43.1%)
Medication dose mg/day 404 (251) 362 (226)
Centre Ayrshire 40 (55.6%) 38 (52.8%)
Glasgow 32 (44.4%) 34 (47.2%)
PANSS Positive 10.9 (3.2) 10.5 (2.7)
Negative 12.8 (4.4) 12.6 (5.3)
Global psychopathology 31.7 (7.5) 29.3 (6.6)
BSI GSI 1.32 (0.80) 1.05 (0.70)
PBIQ Self v. Illness 9.3 (2.7) 8.9 (2.9)
Entrapment 10.2 (2.4) 10.1 (2.8)
Shame 7.2 (2.1) 7.0 (1.8)
Humiliation 4.5 (0.8) 4.6 (1.0)
Loss 7.8 (2.0) 7.2 (2.4)
RSES Total score 24.7 (6.3) 22.8 (5.4)
Duration illness months 113 (81) 114 (84)
History relapse* Yes 37 (52.9%) 38 (56.7%)
No 33 (47.1%) 29 (43.3%)
History admission* Yes 27 (38.6%) 35 (52.2%)
No 43 (61.4%) 32 (48.8%)
SFS Withdrawal 9.3 (2.5) 9.7 (2.4)
Interpersonal 6.5 (1.9) 6.6 (2.0)
Performance 26.1 (6.7) 27.0 (6.2)
Competence 34.9 (3.9) 36.0 (3.4)
Recreation 14.7 (6.1) 13.7 (5.5)
Prosocial 12.6 (8.3) 12.0 (6.3)
Employment 3.0 (3.0) 2.9 (3.1)
PANSS, Positive and Negative Syndrome Scale ; BSI, Brief Symptom Inventory; PBIQ, Personal Beliefs about Illness Questionnaire ; RSES,
Rosenberg Self-Esteem Scale ; SFS, Social Functioning Scale ; GSI, Global Severity Index; NOS, not otherwise speciﬁed.
* Two years pre-entry.
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randomized to CBT (N=72) or TAU (N=72).
Table 1 shows the baseline characteristics of
study participants. There were no appreciable
diﬀerences between the CBT and TAU groups
except that the CBT group had a seemingly
lower self-esteem as measured by the Rosenberg
Self-Esteem Scale.
Treatment received during study period
During the study period the CBT group received
a median (range) 6 (0–14) number of out-patient
medical consultations and 28.5 (0–86) number
of community mental health team contacts. The
TAU group received a median (range) 7 (0–21)
number of out-patient medical consultations
and 27.5 (0–100) number of community mental
health team contacts. The CBT group received
an additional median (range) of 5 (0–6) engage-
ment sessions between entry and 12 weeks.
Twenty-eight CBT participants received a
median (range) of 5 (2–16) number of targeted
CBT sessions.
Admission/relapse
The Kaplan–Meier plot of time to admission is
illustrated in Fig. 2. During the study period 11
(15.3%) participants in the CBT group were
admitted to hospital compared to 19 (26.4%)
of the TAU group (hazard ratio (HR)=0.53,
P=0.089, 95% CI 0.25, 1.10, NNT=9). Fol-
lowing adjustment for the baseline variables
shown in Table 1 the diﬀerence between the
742 Case notes screened
Principal reason for exclusion (N = 505)
3 Outside age range
5 No antipsychotic medication
86 Incorrect diagnosis
204 Not relapse prone
6 Deceased
21 Moved out of area
45 Drug/alcohol dependence
135 Severe positive symptoms
237 Fulfilled initial criteria
93 Failed entry criteria
24 Not approached by keyworker
15 Excluded by RMO
38 Refused
16 Diagnosis incorrect
144 Allocated to treatment
CBT
Completed trial
Dropped out
Reasons
Refused treatment
Withdrew following relapse
Uncertain
(N = 72)
(N = 66)
(N = 6)
(N = 3)
(N = 1)
(N = 2)
TAU
Completed trial
Dropped out
Reasons
Refused assessments
Uncertain
(N = 72)
(N = 67)
(N = 5)
(N = 2)
(N = 3)
FIG. 1. Recruitment and allocation of participants.
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randomized treatment groups in reduction
in admission to hospital reduced further and
became statistically signiﬁcant (HR=0.29,
P=0.032, 95% CI 0.09, 0.90). In addition, CBT
participants had a total of 917 days spent
in hospital compared to 1694 days for TAU
participants. The Kaplan–Meier plot of time to
relapse is illustrated in Fig. 3. A total of 13
(18.1%) participants in CBT relapsed compared
to 25 (34.7%) in TAU (HR=0.47, P=0.028,
95% CI 0.24, 0.92, NNT=6). Following ad-
justment for baseline variables as above the re-
duction in relapse between the treatment groups
reduced further (HR=0.29, P=0.008, 95% CI
0.12, 0.73).
Secondary outcomes
Table 2 illustrates baseline and 12 month scores
on the Positive and Negative Syndrome Scale
and Social Functioning Scale for the CBT and
TAU groups. The change over baseline, and
then the mean diﬀerence (with 95% CI) in this
change over baseline between treatment groups
are also shown. At 12 months the CBT group
showed greater improvement in positive symp-
toms (x1.10, P=0.028, 95% CIx2.08,x0.12)
negative symptoms (x1.89, P=0.016, 95% CI
x3.39, x0.35), global psychopathology
(x4.34, P=0.0005, 95% CI x6.75, x1.93),
performance of independent functions (2.83,
P=0.013, 95% CI 0.61, 5.05) and prosocial ac-
tivities (4.05, P=0.0024, 95% CI 1.46, 6.64).
These ﬁndings were essentially conﬁrmed after
adjustment for the relevant set of covariates lis-
ted in Table 1. Table 3 illustrates the number
of participants whose magnitude of change is
greater than two baseline standard deviations
(lower or higher). A total of nine participants in
CBT made clinically signiﬁcant improvements
in prosocial functioning compared to one in
TAU (P=0.017).
DISCUSSION
The current study is the ﬁrst to examine the ef-
fectiveness of CBT delivered as an early inter-
vention strategy designed to prevent relapse in
schizophrenia. This study diﬀers from previous
studies of CBT for schizophrenia, which have
included participants on the basis of having
severe and distressing positive psychotic symp-
toms which are resistant to antipsychotic medi-
cation (Tarrier et al. 1993, 1998; Kuipers et al.
1997; Pinto et al. 1999; Sensky et al. 2000), or
participants experiencing an acute phase of
psychosis (Drury et al. 1996a, b). Therefore, the
interventions evaluated in these studies have
principally focused on the frequency and dis-
tress of psychotic symptoms such as delusions
and hallucinations, with relapse prevention as
an important, albeit secondary outcome. In
contrast, our study included participants who
were stabilized out-patients, and whose positive
symptoms had been largely responsive to pre-
vious antipsychotic treatment but who never-
theless remained relapse prone. In addition,
during this study CBT was delivered as a tar-
geted intervention at the appearance of early
signs suggestive of relapse and principally fo-
cused on the modiﬁcation of negative beliefs
about relapse (e.g. ‘I am going to relapse and
have no control over what is happening to me’)
and the development of cognitive and beha-
vioural coping strategies to control relapse.
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FIG. 2. Kaplan–Meier plot of time to hospital admission for
cognitive behaviour therapy (CBT) and treatment as usual (TAU).
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FIG. 3. Kaplan–Meier plot of time to relapse for cognitive behav-
iour therapy (CBT) and treatment as usual (TAU).
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The results of this study indicate that target-
ing CBT during the early stages of relapse
results in reduced relapse rate (18.1% versus
34.7%) but not admission rates (15.3% versus
26.4%) over 12-months. The failure to detect
a statistically signiﬁcant diﬀerence in admission
rates between CBT and TAU may well be due
to the sample size of the study. In calculating
the sample size necessary for the study we hy-
pothesized a proportional change of 50% in the
proportion of participants with a relapse. Our
ﬁndings were in line with this hypothesis. How-
ever, based on previous research (Gaebel &
Pietzcker, 1985) we assumed an underlying re-
lapse rate of 50% in TAU. Our ﬁndings on re-
lapse and admission in TAU were less than what
we had originally expected. This may be due to
the nature of TAU itself. In the main partici-
pants in both arms of the study were seen on
a fortnightly basis by their community-based
key workers, usually psychiatric nurses and on a
bi-monthly basis by their psychiatrist. There-
fore, in routine care, key workers may well
have being identifying and responding to early
signs of relapse. In a recent study by Herz
et al. (2000) 82 participants were randomized
to either Treatment as Usual (TAU) or an ex-
perimental group: ‘Program for Relapse Pre-
vention’ (PRP). PRP consisted of education
on early signs for the participants and their
families, active monitoring of early signs, clini-
cal interventions within 24 to 48 hours of
identiﬁcation of a ‘prodromal ’ episode which
included of crisis problem solving, supportive
therapy, and increased medication as required.
Table 3. Clinically signiﬁcant changes for
Social Functioning Scale components
SFS component
fx2 S.D. o2 S.D.
CBT TAU P CBT TAU P
Withdrawal 1 2 0.62 4 3 1.00
Interpersonal 0 1 0.49 6 1 0.12
Performance 0 2 0.24 7 3 0.32
Competence 1 0 1.00 3 1 0.62
Recreation 1 1 1.00 1 1 1.00
Pro-social 1 0 1.00 9 1 0.017
Employ 0 0 1.00 4 5 0.74
Data shown are number of subjects whose magnitude of change
over baseline at 12 months is greater than two baseline standard
deviations, lower or higher (fx2 S.D. oro2 S.D.). P values given are
for Fisher Exact Tests for comparing the number of subjects lower
thanx2 S.D.s below baseline between the two treatment groups, and
also for the number higher than 2 S.D. above baseline.
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In addition, weekly supportive group therapy
emphasizing coping skills or supportive indi-
vidual therapy sessions were oﬀered to partici-
pants, and multifamily psychoeducation groups
were oﬀered to carers. Over 18 months, there
was a signiﬁcant reduction in relapse rate among
the PRP group (7/41, 17%) compared to TAU
(14/41, 34%). On the one hand, as the study
intervention was a package designed to pre-
vent relapse it was not possible to discern the
inﬂuence of early signs monitoring and the
psychological interventions alone. However, on
the other hand, clinicians in PRP identiﬁed
more early signs episodes before participants
met objective criteria for relapse than their TAU
counterparts. This supports the hypothesis that
early detection (the independent variable) was
successfully manipulated. In our study we did
not record the number of early signs episodes
identiﬁed by routine care providers and this is
an important methodological limitation, which
should be borne in mind in interpreting the re-
sults of our study. Furthermore, as our assessors
were not blind to treatment there is the possi-
bility that they were more sensitive to partici-
pants receiving CBT and therefore there is a
problem of potential bias. For this reason hos-
pital admission provides the best evidence of the
eﬀectiveness of this form of CBT. We attempted
to maintain the independence of the assessors by
relying on changes in early signs completed by
the participants to initiate targeted CBT. Where
early signs were not returned, assessors checked
the status of participants with their respective
key workers. If there were changes or circum-
stances suggestive of an increase in relapse risk,
assessors did not recruit the participant to tar-
geted CBT, but informed the therapist who then
made contact in order to conduct an assessment
for targeting. Therefore, in order to rectify these
methodological shortcomings future studies
would include blind assessors, and make sys-
tematic recordings of early signs episodes
identiﬁed prior to objective relapse in both the
experimental and control group. In addition, a
study with 422 participants (211 in each group)
would have 80% power to detect (a<0.05) a
proportionate reduction in admission rates of
26% to 15% for CBT versus TAU (Pocock,
1996).
Notwithstanding these important method-
ological limitations, the results found in this
study are comparable with other studies (Ho-
garty et al. 1997a, b ; Linszen et al. 1998; Herz
et al. 2000), which have included an individual-
ized approach to relapse prevention in schizo-
phrenia. Hogarty et al. (1997a, b) evaluated
personal therapy (PT), a psychological treat-
ment designed to improve control over relapse.
PT involved three phases: (1) psychoeducation
and the identiﬁcation of aﬀective, cognitive and
physiological experience of stress ; (2) stress
management techniques and social skills train-
ing; and (3) skills training in managing criticism
and resolving conﬂict. Among patients living
with family PT was associated with a relapse
rate of 13% over 3 years. However, among
those living alone, PT led to more psychotic
relapses. The authors argue that this arose be-
cause PT may have served as a stressor for those
without support from their family and having
to cope with living in the community alone. In
particular during the study this group of par-
ticipants already had high levels of stress includ-
ing ﬁnancial problems and conﬂict with staﬀ. In
our study, many of our participants were living
alone, but were also stabilized and relatively
well supported by their community mental
health teams. On the other hand, Linszen et al.
(1998) found that combined family and indi-
vidual intervention was associated with a re-
lapse rate of 15% over 12 months, however
following transfer to standard services relapse
rate increased in the following 2 years to 64%. It
is not at present known whether the eﬀects of
CBT on relapse/admission rate in our study are
sustained after 12 months, and a further longer
term follow-up study of participants in this trial
is planned.
We also found that following adjustment for
baseline covariates, the reduction in admission
rate between the two randomized treatment
groups was further reduced and reached stat-
istical signiﬁcance. This suggests that factors
other than treatment are associated with ad-
mission to hospital with a psychotic relapse.
For example, numerous factors have been found
to be associated with relapse including early
adolescent adjustment (Robinson et al. 1999),
duration of untreated psychosis (Crow et al.
1986), non-adherence with medication (Kemp
et al. 1998), expressed emotion (Kavanagh,
1992) and coping style (Hultman et al. 1997).
In addition, there is evidence to suggest that
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patients themselves monitor and regulate their
symptoms in order to prevent relapse (Breier
& Strauss, 1983; McCandless-Glimcher et al.
1986; Hultman et al. 1997). Indeed, our ap-
proach to treatment focused on participants’
beliefs and coping responses to early signs of
increased risk of relapse. Further prognostic
research investigating the role of these factors
in mediating risk of future relapse is merited.
Consistent with other studies of CBT (Tarrier
et al. 1993, 1998; Drury et al. 1996a, b ; Kuipers
et al. 1997; Pinto et al. 1999; Sensky et al. 2000)
patients receiving CBT had signiﬁcant im-
provements over TAU in positive symptoms,
negative symptoms and global psychopathology.
However, unlike previous studies of CBT, this
study also found signiﬁcant improvements in
two social functioning domains, performance of
independent functioning (e.g. shopping, looking
after money) and prosocial activities (e.g. going
to the cinema, visiting family). Indeed, 12.5%
(9/72) of participants in CBT made a clinically
signiﬁcant improvement in their prosocial func-
tioning; that is o2 standard deviations above
their baseline scores. Other treatments, which
explicitly target relapse risk, have also found
improvements in social functioning. For ex-
ample, family intervention studies have shown
that participants who receive family intervention
also make improvements in their social func-
tioning (Spiegel & Wissler, 1987; Barrowclough
& Tarrier, 1990; Hogarty et al. 1991; Vaughn
et al. 1992; Xiang et al. 1994). In studies of
relapse prevention in bipolar disorder (Perry
et al. 1999; Lam et al. 2000; Scott et al. 2001)
signiﬁcant improvements in social functioning
have also been demonstrated. Drury et al.
(2000) found that those who did not relapse
more than once over 5 years reported increased
control over psychosis. Iqbal et al. (2000) found
that increased awareness of psychosis and a
perception of being unable to control relapse
was associated with the development of post-
psychotic depression. Therefore interventions,
which confer clinical stability, may reduce the
fear of relapse and improve perceived control
over psychosis. This may facilitate individuals
adopting new or more adaptive coping stra-
tegies, which enhance social and interpersonal
functioning, as opposed to using withdrawal or
avoidance orientated coping (Hultman et al.
1997). Prospective research investigating the
role of appraisals of relapse and coping in the
recovery of social and interpersonal functioning
in schizophrenia is needed.
To summarize, CBT had a beneﬁcial eﬀect
on relapse and admission over 12 months.
Additional beneﬁts were also observed for posi-
tive symptoms, negative symptoms, and global
psychopathology. In addition, improvements
were found in areas of social functioning in-
cluding independence and prosocial activities.
Treatment seemed acceptable with only three
patients refusing treatment. In addition, the rate
of dropout was low in both groups. However,
this was a study, which did not have blind as-
sessors, and although these results are encour-
aging they should be replicated with control for
the attentional eﬀects of the CBT. There also
should be longer-term follow-up to evaluate
whether treatment gains achieved over 12
months are sustained.
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